Recent

% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • scistats scistats Apr 27, 2013 11:50 PM Flag

    Likelihood of Novartis cHTS re-up = 100%

    METHOD FOR TREATING HAEMATOLOGICAL CANCERS
    United States Patent Application 20120258940 (Zalicus cHTS used)

    KEY THERAPEUTIC TARGETS
    Novartis Oncology is developing compounds for a broad range of therapeutic targets which are
    grouped into eight categories in this Pipeline brochure:

    •RAS-RAF-MEK-ERK (extracellular signal regulated kinase) pathway inhibitors
    •Fibroblast growth factor receptor (FGFR) inhibitors

    Abstract:

    The present invention relates to a combination which comprises (a) a FGFR inhibitor and (b) a glucocorticoid receptor modulator, or a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of haematological cancers; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.

    Publication Date:10/11/2012
    Filing Date:12/17/2010

    Claims: A combination of (a) a FGFR inhibitor and (b) a modulator of glucocorticoid receptor, wherein (a) and (b) are present in each case in free form, complex form or in the form of a pharmaceutically acceptable salt.

    Novartis Oncology currently has two FGFR
    inhibitors in development: Dovitinib (TKI258) and BGJ398

    DOVITINIB
    (TKI258)

    •Phase I/II (Confirmatory) - Breast Cancer
    •Phase I/II (Confirmatory) - Endometrial cancer
    •Phase I/II (Confirmatory) - Hepatocellular carcinoma
    •Phase III or Pivotal (Registration Trials) - Renal cell carcinoma (RCC)

    Mode of Action: FGFR inhibitor
    Tumor Type: Solid

    One lung cancer patient with an FGFR1/CEP8 ratio of 2.6 by FISH analysis responded to 100 mg of NVP-BGJ398 with a 33% reduction in target lesions by CT scan at 8 weeks, confirmed at 12 weeks, and a substantial SUV decrease on PET. These observations provide early evidence that inhibition of the FGFR pathway is effective in patients with FGFR dependent cancers.

    Sentiment: Strong Buy

 
ZLCS
0.00(0.00%)